UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): March 1, 2018

 

MEDOVEX CORP.

(Exact Name of Registrant as Specified in Charter)

 

Nevada   001-36763   46-3312262
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

3060 Royal Boulevard South, Suite 150
Alpharetta, Georgia
  30022
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (844) 633-6839

 

Copies to:

 

Harvey Kesner, Esq.

Arthur S. Marcus, Esq.

Sichenzia Ross Ference Kesner LLP

61 Broadway, 32nd Floor

New York, New York 10006

(212) 930-9700

(212) 930-9725 (fax)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

Item 1.01 Entry Into A Material Definitive Agreement

 

On February 26, 2018, MedoveX Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with selected accredited investors (each an “Investor” and collectively, the “Investors”). Pursuant to the terms of the Securities Purchase Agreement, the Company sold an aggregate of 770,000 shares of Common Stock and 385,000 Warrants to purchase Common Stock (the “Offering”). The Offering resulted in $308,000 in gross proceeds to the Company. The Warrants have a five year term commencing six (6) months from issuance and an exercise price of $0.75. The shares were sold at $0.40 per share. The Warrants are exercisable on a cashless basis in the event that the underlying shares are not subject to an effective registration statement. The Shares of Common Stock sold in the Offering were registered in the Company’s effective registration statement on Form S-3 (Reg No. 333-217411). The foregoing description of the terms of the Securities Purchase Agreement and Warrant is not complete and is qualified in it’s entirety by the full text of the Securities Purchase Agreement and Warrant, which are filed as Exhibit 10.1 and 10.2 to the Current Report on Form 8-K and are incorporated by reference herein.

 

Each of the Investors is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended (the “Act”), and the warrants were sold to them in reliance on the exemption from registration provided by Rule 506 and Section 4(2) of the Act.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

See Item 1.01 above, with respect to the sale of the Warrants.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit Number   Description
10.1   Form of Securities Purchase Agreement, by and between the Company and Investors
10.2   Form of Warrant issued by MedoveX Corporation to each of the Investors

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 1, 2018 MEDOVEX CORPORATION
     
  By: /s/ Jarrett Gorlin
    Jarrett Gorlin
    Chief Executive Officer